Allergan Aesthetics presents research at 2022 American Society for Dermatologic Surgery meeting

Allergan Aesthetics presented eight scientific abstracts from its leading portfolio of aesthetic products and treatments at the American Society for Dermatologic Surgery (ASDS) meeting in Denver this week.

Researchers from the AbbVie company spotlighted global post-marketing surveillance data on the reported rates of delayed-onset nodules presenting four or more weeks after injection of hyaluronic acid fillers based on the Vycross technology platform. Analysis of 15 years of data demonstrated the global reported rate of delayed-onset nodules associated with dermal fillers on the Vycross technology platform is low (<0.016%). Inflammatory nodules, which typically require intervention/treatment, were reported less frequently than non-inflammatory nodules.

Dr DiAnne Davis, a board-certified cosmetic dermatologist from Texas also discussed the new Forces of Beauty report from Allergan Aesthetics' DREAM (Driving Racial Equity in Aesthetic Medicine) Initiative.

"Our scientific excellence continues to help drive advances in aesthetic medicine, as well as bring impactful treatments to our customers and patients globally," said Darin Messina, senior vice president, Allergan Aesthetics R&D. "The data presented at ASDS reinforces our leadership in aesthetics and also the commitment of our research and development team to drive innovation for the industry and share learnings with the broader medical community."

Results were also presented from three clinical studies showcasing a customizable platform with a patent-pending LTN Complex, addressing the appearance of facial hyperpigmentation in a wide range of demographic populations.